ProQuest Investments

SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. The company utilizes its proprietary technology platform, SomaScan, which allows for the measurement of proteins with a precision comparable to DNA measurement. This technology enhances the understanding of the molecular bases of health and disease, surpassing traditional genomic methods. SomaLogic develops and offers SOMAmers, modified nucleic acid-based protein-binding reagents, and provides diagnostic tests and protein measurement solutions for various diseases, including those in oncology, neurology, and cardiovascular health. Their products serve multiple applications, including life sciences research, therapeutic drug development, and clinical diagnostics, making significant contributions to the fields of biological and medical sciences. Founded in 1999, SomaLogic continues to advance the capabilities of proteomics in both research and clinical settings.

ReVision Optics, Inc. is a company based in Lake Forest, California, specializing in the design, manufacture, and delivery of implantable products aimed at treating presbyopia, a condition that affects near vision due to aging. The company offers the PRESBYLENS Corneal Inlay, a patented refractive surgery solution that enhances near vision for patients experiencing this common age-related vision loss. By providing innovative optical technology, ReVision Optics enables ophthalmology professionals to deliver improved eyesight solutions to their patients. Founded in 1996 and originally named IntraLens Vision, Inc., the company rebranded in 2005 to align with its focus on presbyopia treatments.

Agile Therapeutics is a women's healthcare company dedicated to addressing the unmet health needs of women through the development and commercialization of prescription contraceptive products. The company's lead product, Twirla, is a once-weekly transdermal patch that delivers a combination of levonorgestrel and ethinylestradiol, providing a non-daily contraceptive option. In addition to Twirla, Agile Therapeutics is advancing a pipeline of related products, including various regimens designed to offer customizable menstrual cycle management options, such as AG200-ER for extended cycles and AG200-SP for lighter periods. The firm's proprietary Skinfusion technology facilitates effective drug delivery through the skin. Headquartered in Princeton, New Jersey, Agile Therapeutics aims to enhance women's reproductive health by providing innovative contraceptive solutions.

SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. The company utilizes its proprietary technology platform, SomaScan, which allows for the measurement of proteins with a precision comparable to DNA measurement. This technology enhances the understanding of the molecular bases of health and disease, surpassing traditional genomic methods. SomaLogic develops and offers SOMAmers, modified nucleic acid-based protein-binding reagents, and provides diagnostic tests and protein measurement solutions for various diseases, including those in oncology, neurology, and cardiovascular health. Their products serve multiple applications, including life sciences research, therapeutic drug development, and clinical diagnostics, making significant contributions to the fields of biological and medical sciences. Founded in 1999, SomaLogic continues to advance the capabilities of proteomics in both research and clinical settings.

Telormedix is a biopharmaceutical company specializing in the development of targeted therapies that harness the innate immune system to treat cancer and autoimmune diseases. The company focuses on creating innovative drug formulations based on a clinically active small molecule compound, which has a recognized safety profile and is aimed at specific immunotherapeutic targets. This approach is designed to enhance treatment options for cancer patients, ultimately leading to improved medical outcomes. Telormedix aims to advance the field of immunotherapy by delivering effective solutions for both cancer and infectious diseases.

Immune Design Corp. is a clinical-stage immunotherapy company headquartered in Seattle, Washington, that specializes in developing innovative treatments for cancer through in vivo methods that empower the immune system to combat disease. The company utilizes its ZVex and GLAAS discovery platforms to create a new generation of immune-based products. Its primary product candidate, G100, is currently undergoing Phase II clinical trials for follicular non-Hodgkin lymphoma, while another candidate, CMB305, focuses on enhancing tumor-specific cytotoxic T cells. Immune Design's research aims to overcome limitations of existing oncological therapies, and the company has established collaboration and license agreements with Sanofi Pasteur. Founded in 2008, Immune Design operates as a subsidiary of Merck & Co., Inc.

ReVision Optics, Inc. is a company based in Lake Forest, California, specializing in the design, manufacture, and delivery of implantable products aimed at treating presbyopia, a condition that affects near vision due to aging. The company offers the PRESBYLENS Corneal Inlay, a patented refractive surgery solution that enhances near vision for patients experiencing this common age-related vision loss. By providing innovative optical technology, ReVision Optics enables ophthalmology professionals to deliver improved eyesight solutions to their patients. Founded in 1996 and originally named IntraLens Vision, Inc., the company rebranded in 2005 to align with its focus on presbyopia treatments.

Mevion Medical Systems, Inc. is a developer of proton therapy systems aimed at enhancing cancer treatment worldwide. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company has pioneered modern proton therapy technology. Its flagship product, the MEVION S250 Proton Therapy System, is designed to retain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating advanced patented technology, Mevion aims to improve beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment centers and clinicians globally.

ReVision Optics, Inc. is a company based in Lake Forest, California, specializing in the design, manufacture, and delivery of implantable products aimed at treating presbyopia, a condition that affects near vision due to aging. The company offers the PRESBYLENS Corneal Inlay, a patented refractive surgery solution that enhances near vision for patients experiencing this common age-related vision loss. By providing innovative optical technology, ReVision Optics enables ophthalmology professionals to deliver improved eyesight solutions to their patients. Founded in 1996 and originally named IntraLens Vision, Inc., the company rebranded in 2005 to align with its focus on presbyopia treatments.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

Telormedix is a biopharmaceutical company specializing in the development of targeted therapies that harness the innate immune system to treat cancer and autoimmune diseases. The company focuses on creating innovative drug formulations based on a clinically active small molecule compound, which has a recognized safety profile and is aimed at specific immunotherapeutic targets. This approach is designed to enhance treatment options for cancer patients, ultimately leading to improved medical outcomes. Telormedix aims to advance the field of immunotherapy by delivering effective solutions for both cancer and infectious diseases.

Mevion Medical Systems, Inc. is a developer of proton therapy systems aimed at enhancing cancer treatment worldwide. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company has pioneered modern proton therapy technology. Its flagship product, the MEVION S250 Proton Therapy System, is designed to retain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating advanced patented technology, Mevion aims to improve beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment centers and clinicians globally.

MethylGene Inc. (TSX:MYG) is a publicly-traded, clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics with a focus on cancer. The Company's product candidates include: MGCD265, an oral, multi-targeted kinase inhibitor targeting the Met, VEGF, Ron and Tie-2 receptor tyrosine kinases that is in multiple clinical trials for cancer; MGCD290, a fungal Hos2 inhibitor for use in combination with fluconazole for serious fungal infections which has completed Phase I clinical studies; and mocetinostat (MGCD0103), an oral, isoform-selective HDAC inhibitor for cancer which has been in multiple Phase II clinical trials and is currently in a Phase II trial in refractory or relapsed follicular lymphoma. Mocetinostat is licensed to Taiho Pharmaceutical Co. Ltd in certain Asian countries. A fourth compound discovered using MethylGene's HDAC platform, EVP-0334 - a potential cognition enhancing agent for neurodegenerative diseases has successfully completed Phase I trials sponsored by EnVivo Pharmaceuticals Inc. MethylGene also has a funded collaboration with Otsuka Pharmaceutical Co. Ltd. for applications in ocular diseases using the Company's proprietary kinase inhibitor chemistry.

ReVision Optics, Inc. is a company based in Lake Forest, California, specializing in the design, manufacture, and delivery of implantable products aimed at treating presbyopia, a condition that affects near vision due to aging. The company offers the PRESBYLENS Corneal Inlay, a patented refractive surgery solution that enhances near vision for patients experiencing this common age-related vision loss. By providing innovative optical technology, ReVision Optics enables ophthalmology professionals to deliver improved eyesight solutions to their patients. Founded in 1996 and originally named IntraLens Vision, Inc., the company rebranded in 2005 to align with its focus on presbyopia treatments.

Predictive Biosciences, Inc., a molecular diagnostics company, develops diagnostic products for informed cancer management. It specializes in proteomics, diagnostics, oncology, and tumor biomarkers. The company offers biomarkers and proteomics-based assay technologies. These assays detect urinary biomarkers associated with the physiological changes resulting from cancer development and progression. It also provides Triage Monitoring Assay, which allows physicians to delay and invasive diagnostic procedures; Interval Monitoring Assay that is for surveillance and detection of cancer between follow-ups; and Stratification Assay, which supports a physician's decision to manage a patient. Predictive Biosciences, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

Agile Therapeutics is a women's healthcare company dedicated to addressing the unmet health needs of women through the development and commercialization of prescription contraceptive products. The company's lead product, Twirla, is a once-weekly transdermal patch that delivers a combination of levonorgestrel and ethinylestradiol, providing a non-daily contraceptive option. In addition to Twirla, Agile Therapeutics is advancing a pipeline of related products, including various regimens designed to offer customizable menstrual cycle management options, such as AG200-ER for extended cycles and AG200-SP for lighter periods. The firm's proprietary Skinfusion technology facilitates effective drug delivery through the skin. Headquartered in Princeton, New Jersey, Agile Therapeutics aims to enhance women's reproductive health by providing innovative contraceptive solutions.

Adastra Pharmaceuticals is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative therapies for cancer treatment. Founded in 2005 and formerly known as Tragara Pharmaceuticals, the company specializes in proprietary medicines aimed at improving patient outcomes in oncology. One of its key products is an oral multi-kinase inhibitor, designed to effectively inhibit critical cyclin-dependent kinases, thereby enhancing the survival and quality of life for patients with various cancers. Adastra Pharmaceuticals is dedicated to advancing patient care through its responsible approach to oncology.

Orthocon is a medical therapeutics company focused on developing innovative absorbable products specifically for orthopedic and spine surgeries. The company's core offering is the HEMASORB Absorbable Bone Hemostat Matrix, which is a ready-to-use, biocompatible, and water-resistant putty designed to effectively stop bone bleeding when applied to damaged or cut bones. Orthocon manufactures, markets, and sells these implantable products, aiming to enhance surgical outcomes and improve patient care in orthopedic procedures.

Gloucester Pharmaceuticals is a biopharmaceutical company focused on developing cancer therapeutics, specifically targeting hematological malignancies. Owned by Celgene, the company specializes in acquiring clinical-stage oncology drug candidates and advancing them through regulatory approval and commercialization. Its primary compound, romidepsin, is a late-stage drug candidate classified as a histone deacetylase (HDAC) inhibitor. Romidepsin has demonstrated potential efficacy for various hematological cancers, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma. Gloucester retains worldwide exclusive rights to romidepsin, which has shown promise as a potent inhibitor of several classes of HDACs, thus positioning the company as a significant player in the oncology therapeutic landscape.

BioSyntech, Inc. develops biotherapeutic thermogels designed for tissue repair and delivery of therapeutic agents. Its technology platform is BST-Gel, a family of hydrogels based on chitosan, a natural biopolymer derived from crustacean shells. The company’s lead products in clinical trials include BSTCarGel for cartilage repair; BST-DermOn for wound healing; and BST-InPod for the treatment of chronic pain due to plantar fat pad atrophy in the heel and forefoot. Biosyntech has a collaboration with Nicholas Piramal India, Ltd. to involve in the clinical studies for BST-InPod, which is being developed to alleviate the chronic pain associated with foot fat pads. The company was incorporated in 1994 and is headquartered in Laval, Canada.

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company headquartered in Fremont, California, established in 2006. The company specializes in developing innovative drug delivery technologies aimed at addressing unmet medical needs. Its primary focus is on providing therapeutics for migraine sufferers through its proprietary intracutaneous microneedle system, which facilitates rapid systemic administration and absorption of medications. Zosano's lead product candidate, Qtrypta (M207), is a formulation of zolmitriptan designed to offer an improved pharmacokinetic profile compared to traditional dosage forms. By leveraging its advanced delivery system, Zosano Pharma aims to enhance patient outcomes and expand the potential for commercialization of its therapeutic products.

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Their development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.

Orthocon is a medical therapeutics company focused on developing innovative absorbable products specifically for orthopedic and spine surgeries. The company's core offering is the HEMASORB Absorbable Bone Hemostat Matrix, which is a ready-to-use, biocompatible, and water-resistant putty designed to effectively stop bone bleeding when applied to damaged or cut bones. Orthocon manufactures, markets, and sells these implantable products, aiming to enhance surgical outcomes and improve patient care in orthopedic procedures.

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.

Telormedix is a biopharmaceutical company specializing in the development of targeted therapies that harness the innate immune system to treat cancer and autoimmune diseases. The company focuses on creating innovative drug formulations based on a clinically active small molecule compound, which has a recognized safety profile and is aimed at specific immunotherapeutic targets. This approach is designed to enhance treatment options for cancer patients, ultimately leading to improved medical outcomes. Telormedix aims to advance the field of immunotherapy by delivering effective solutions for both cancer and infectious diseases.

Gemin X Pharmaceuticals focuses on the discovery, development, and commercialization of innovative cancer therapeutics aimed at enhancing patient outcomes. The company's research has centered on the Bcl-2 cell death regulation pathway, leading to the development of GX15-070 (obatoclax), a small molecule designed to selectively trigger programmed cell death, or apoptosis, and potentially induce cancer cell autophagy. Obatoclax has demonstrated promising results in preclinical and early clinical trials and is currently undergoing Phase 2 clinical trials as both a standalone treatment and in combination with other therapies. Additionally, Gemin X is involved in developing other oncology products, including GMX1777, which inhibits NAD+ synthesis. The patent for obatoclax is secured until 2025, reinforcing the company's commitment to advancing cancer treatment options.

Sopherion Therapeutics, LLC is a privately held biopharmaceutical company headquartered in Princeton, New Jersey with offices in Cheshire, Connecticut, Estero, Florida and an operating subsidiary, Sopherion Therapeutics Canada, in Toronto, Canada. Sopherion Therapeutics LLC is a specialty biopharmaceutical company with an exclusive licensing agreement with Zeneus Pharma Ltd., now Cephalon, Inc., for the commercialization of Myocet™ (a liposome-encapsulated doxorubicin-citrate complex) in the United States and Canada. Sopherion’s current business focus is the execution of a Phase III, global, randomized, registration trial for first line therapy of invasive, metastatic breast cancer and the development and commercialization of Sopherion’s lead agent, Myocet™. Myocet is being investigated in an FDA agreed upon registration trial in combination with two other drugs, Herceptin® (Trastuzumab) and Taxol (Paclitaxel) vs. Herceptin® and Taxol alone, the current standard of care for first line HER-2-overexpressing metastatic breast cancer. Myocet™, a liposome-encapsulated doxorubicin with reduced cardiotoxicity, is a nanotechnology product that localizes into tumor vasculature and in contrast to parental doxorubicin avoids homing to the heart. This 363 patient global trial in twelve countries has as of 03/06/09 been fully recruited. Unblinding is anticipated by the summer of 2010 with NDA submission for full approval following within 6 months. Myocet® is already a registered drug in Canada, where Sopherion has commercial rights and in Europe where Cephalon has commercial rights for use in first line metastatic breast cancer in combination with cyclophosphamide.; Their Phase III trial is based on a Phase II trial, supported by Roche, which gave a 96% response rate and two and a half year median progression free survival for patients with metastatic breast cancer.

Excaliard Pharmaceuticals is a biotechnology company that specializes in the development and commercialization of antisense drugs aimed at treating scarring and other fibrotic diseases. The firm focuses on creating targeted therapeutics that address dermatological disorders, providing innovative solutions for patients suffering from various skin conditions. By employing advanced antisense technology, Excaliard aims to improve treatment outcomes for individuals with fibrotic diseases, enhancing their quality of life through effective localized therapies.

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company headquartered in Fremont, California, established in 2006. The company specializes in developing innovative drug delivery technologies aimed at addressing unmet medical needs. Its primary focus is on providing therapeutics for migraine sufferers through its proprietary intracutaneous microneedle system, which facilitates rapid systemic administration and absorption of medications. Zosano's lead product candidate, Qtrypta (M207), is a formulation of zolmitriptan designed to offer an improved pharmacokinetic profile compared to traditional dosage forms. By leveraging its advanced delivery system, Zosano Pharma aims to enhance patient outcomes and expand the potential for commercialization of its therapeutic products.

LEAD Therapeutics, Inc. is a chemistry-driven drug discovery company focused on delivering novel and differentiated small molecule IND candidates against clinically validated therapeutic targets, focused primarily on the treatment of Cancer and infectious diseases.

5asec is a textile care brand that provides its customers with dry cleaning and laundry services. 5asec provides its services in 3 segments, including basic services: dry cleaning, professional washing and steam ironing, and stain cleaning; professional services: duvet and home linen treatment, alterations services; and carpets, furniture, and leather cleaning; and textile care solutions: maxima treatment, appret finish, anti-moth and dust mites’ repellent solutions, and water repellent treatments. 5asec is headquartered in Geneva, Switzerland.

Adastra Pharmaceuticals is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative therapies for cancer treatment. Founded in 2005 and formerly known as Tragara Pharmaceuticals, the company specializes in proprietary medicines aimed at improving patient outcomes in oncology. One of its key products is an oral multi-kinase inhibitor, designed to effectively inhibit critical cyclin-dependent kinases, thereby enhancing the survival and quality of life for patients with various cancers. Adastra Pharmaceuticals is dedicated to advancing patient care through its responsible approach to oncology.

Alaunos Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for cancer, specifically through adoptive TCR-T cell therapy. The company utilizes a unique gene expression and control technology to deliver DNA that targets neoantigens derived from genomic mutations in solid tumors. This approach aims to enhance the immune response against cancer cells. Alaunos is currently conducting Phase 2 clinical studies to evaluate the efficacy of its therapies, including the immune system cytokine interleukin-12 for breast cancer and advanced melanoma. Additionally, the company is exploring multiple investigational new drug applications for new therapeutic targets, leveraging its advanced technology to improve treatment outcomes for patients.

NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the development of novel drug delivery systems for prescription and over-the-counter drugs. The Company's proprietary oral spray technology delivery system offers the patient the potential for (i) more rapid delivery of drugs to the bloodstream allowing for quicker onset of therapeutic effects compared to conventional oral dosage forms; (ii) increased bioavailability of a drug by avoiding metabolism by the liver; (iii) improved drug safety profile by reducing the required dosage, including possible reduction of side effects; (iv) improved dosage reliability; (v) allowing medication to be taken without water; (vi) avoiding the need to swallow as is the case with many medications; and (vii) improved patient convenience and compliance. The Company plans to develop such products independently and through collaborative arrangements with major pharmaceutical and biotech companies.

Cabrellis Pharmaceuticals Corporation, a specialty pharmaceutical company developing therapies for the treatment of cancer. Cabrellis plans to initiate three separate clinical trials in small cell lung cancer (SCLC) in 2006. The first trial, designed to assess the safety and efficacy of Calsed(TM) in reference to topotecan in the second-line treatment of patients with SCLC who previously responded to platinum-based chemotherapy, is currently underway at multiple clinical trial sites in the United States.

Alaunos Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for cancer, specifically through adoptive TCR-T cell therapy. The company utilizes a unique gene expression and control technology to deliver DNA that targets neoantigens derived from genomic mutations in solid tumors. This approach aims to enhance the immune response against cancer cells. Alaunos is currently conducting Phase 2 clinical studies to evaluate the efficacy of its therapies, including the immune system cytokine interleukin-12 for breast cancer and advanced melanoma. Additionally, the company is exploring multiple investigational new drug applications for new therapeutic targets, leveraging its advanced technology to improve treatment outcomes for patients.

Optimer Pharmaceuticals is a biopharmaceutical company dedicated to discovering, developing, and commercializing anti-infective products, particularly those targeting gastrointestinal infections. The company has advanced two late-stage product candidates, fidaxomicin and Pruvel, which address significant medical needs where existing therapies are inadequate. Optimer's portfolio also includes additional candidates such as CEM-101 and a combination therapy involving OPT-822/OPT-821, reflecting its commitment to developing hospital specialty products that positively impact patient health and the healthcare system. By focusing on treatments for conditions like Clostridium difficile-associated diarrhea, Optimer aims to enhance patient outcomes and alleviate the burden of infectious diseases.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.

Gloucester Pharmaceuticals is a biopharmaceutical company focused on developing cancer therapeutics, specifically targeting hematological malignancies. Owned by Celgene, the company specializes in acquiring clinical-stage oncology drug candidates and advancing them through regulatory approval and commercialization. Its primary compound, romidepsin, is a late-stage drug candidate classified as a histone deacetylase (HDAC) inhibitor. Romidepsin has demonstrated potential efficacy for various hematological cancers, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma. Gloucester retains worldwide exclusive rights to romidepsin, which has shown promise as a potent inhibitor of several classes of HDACs, thus positioning the company as a significant player in the oncology therapeutic landscape.

BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.

As of January 30, 2009, Novacea, Inc. was acquired by Transcept Pharmaceuticals, Inc., in a reverse merger transaction. Novacea, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer. The company’s product candidates include Asentar, which is in Phase III clinical trial for the treatment of androgen-independent prostate cancer and in Phase II clinical trial for the treatment of advanced pancreatic cancer; and AQ4N, a hypoxia-activated prodrug in Phase Ib/IIa clinical trial for the treatment of glioblastoma multiforme. It has license and collaboration agreements with Aventis Pharmaceuticals, Inc.; Oregon Health & Science University; University of Pittsburgh; KuDOS Pharmaceuticals Limited; and BTG International Limited. The company was founded in 2001 and is headquartered in South San Francisco, California.

Conforma Therapeutics Corporation designs and develops drugs for the treatment of cancer. It develops drugs that induce tumor cells to degrade the proteins that promote cancer growth. The company offers HSP90 and CNF1010 which are used for the treatment of cancer. The company was incorporated in 1999 and is based in San Diego, California

Sopherion Therapeutics, LLC is a privately held biopharmaceutical company headquartered in Princeton, New Jersey with offices in Cheshire, Connecticut, Estero, Florida and an operating subsidiary, Sopherion Therapeutics Canada, in Toronto, Canada. Sopherion Therapeutics LLC is a specialty biopharmaceutical company with an exclusive licensing agreement with Zeneus Pharma Ltd., now Cephalon, Inc., for the commercialization of Myocet™ (a liposome-encapsulated doxorubicin-citrate complex) in the United States and Canada. Sopherion’s current business focus is the execution of a Phase III, global, randomized, registration trial for first line therapy of invasive, metastatic breast cancer and the development and commercialization of Sopherion’s lead agent, Myocet™. Myocet is being investigated in an FDA agreed upon registration trial in combination with two other drugs, Herceptin® (Trastuzumab) and Taxol (Paclitaxel) vs. Herceptin® and Taxol alone, the current standard of care for first line HER-2-overexpressing metastatic breast cancer. Myocet™, a liposome-encapsulated doxorubicin with reduced cardiotoxicity, is a nanotechnology product that localizes into tumor vasculature and in contrast to parental doxorubicin avoids homing to the heart. This 363 patient global trial in twelve countries has as of 03/06/09 been fully recruited. Unblinding is anticipated by the summer of 2010 with NDA submission for full approval following within 6 months. Myocet® is already a registered drug in Canada, where Sopherion has commercial rights and in Europe where Cephalon has commercial rights for use in first line metastatic breast cancer in combination with cyclophosphamide.; Their Phase III trial is based on a Phase II trial, supported by Roche, which gave a 96% response rate and two and a half year median progression free survival for patients with metastatic breast cancer.

Iomai Corporation specializes in the discovery and development of vaccines and immune system stimulants using a unique, needle-free approach known as transcutaneous immunization (TCI). This technology utilizes antigen-presenting cells located in the outer layers of the skin to enhance immune responses, allowing for the improvement of existing vaccines and the creation of new ones that can only be administered through this method. Founded in 1997 and based in Gaithersburg, Maryland, Iomai aims to expand the global vaccine market. Following its acquisition by Intercell Ag, the company was rebranded as Intercell USA, Inc. and now operates as a subsidiary of Intercell Biomedical Research & Development AG.

BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.

As of January 30, 2009, Novacea, Inc. was acquired by Transcept Pharmaceuticals, Inc., in a reverse merger transaction. Novacea, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer. The company’s product candidates include Asentar, which is in Phase III clinical trial for the treatment of androgen-independent prostate cancer and in Phase II clinical trial for the treatment of advanced pancreatic cancer; and AQ4N, a hypoxia-activated prodrug in Phase Ib/IIa clinical trial for the treatment of glioblastoma multiforme. It has license and collaboration agreements with Aventis Pharmaceuticals, Inc.; Oregon Health & Science University; University of Pittsburgh; KuDOS Pharmaceuticals Limited; and BTG International Limited. The company was founded in 2001 and is headquartered in South San Francisco, California.

Pharmion is a global biotech company that is dedicated to the hematology and oncology communities. We work in partnership with a network of scientific and clinical advisors to identify and develop products for global hematology and oncology markets. To expand each product's potential, we have established our own regulatory, development and sales and marketing organizations in the United States, Europe, and Australia, and we have developed a third-party distributor network to serve the hematology and oncology markets in 20 additional countries throughout the Middle East, Asia, and Latin America. The global capabilities within our sales, marketing and distribution organization distinguishes us from other companies of a similar size. With our international network we can reach physicians and their patients in more than 30 countries. With proven development and regulatory professionals and an experienced global commercialization team, we concentrate our resources on licensing, developing, and commercializing therapeutic products for the treatment of hematology and oncology patients. Through these efforts, we seek to provide greater therapeutic options to hematologists and oncologists with the ultimate goal of extending survival and improving patients’ quality of life.

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.

Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.

Optimer Pharmaceuticals is a biopharmaceutical company dedicated to discovering, developing, and commercializing anti-infective products, particularly those targeting gastrointestinal infections. The company has advanced two late-stage product candidates, fidaxomicin and Pruvel, which address significant medical needs where existing therapies are inadequate. Optimer's portfolio also includes additional candidates such as CEM-101 and a combination therapy involving OPT-822/OPT-821, reflecting its commitment to developing hospital specialty products that positively impact patient health and the healthcare system. By focusing on treatments for conditions like Clostridium difficile-associated diarrhea, Optimer aims to enhance patient outcomes and alleviate the burden of infectious diseases.

Guava Technologies, Inc. is a manufacturer of biotechnology and medical devices, specializing in the development and design of products for life science research and clinical diagnostics. The company provides a range of solutions, including flow cytometry systems and assays for cell counting, viability, antibody quantification, apoptosis, and cytotoxicity. These products support various applications in cell biology research and drug discovery, with a particular emphasis on HIV/AIDS monitoring. Founded in 1998 and headquartered in Hayward, California, Guava Technologies operates as a subsidiary of Millipore Corp.

Acurian provides solutions needed to recruit, enroll, and retain patients for clinical trials. The company offers recruitment feasibility, site identification and selection, patient recruitment and retention, and cancer solutions. Acurian was founded in 1998 and is based in Horsham, Pennsylvania.